Abstract
People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 129-141 |
| Number of pages | 13 |
| Journal | CNS Drugs |
| Volume | 21 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 19 2007 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
Lack of insight in schizophrenia : Impact on treatment adherence. / Buckley, Peter F; Wirshing, Donna A.; Bhushan, Prameet; Pierre, Joseph M.; Resnick, Seth A.; Wirshing, William C.
In: CNS Drugs, Vol. 21, No. 2, 19.02.2007, p. 129-141.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Lack of insight in schizophrenia
T2 - Impact on treatment adherence
AU - Buckley, Peter F
AU - Wirshing, Donna A.
AU - Bhushan, Prameet
AU - Pierre, Joseph M.
AU - Resnick, Seth A.
AU - Wirshing, William C.
PY - 2007/2/19
Y1 - 2007/2/19
N2 - People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.
AB - People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.
UR - http://www.scopus.com/inward/record.url?scp=33846967064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846967064&partnerID=8YFLogxK
U2 - 10.2165/00023210-200721020-00004
DO - 10.2165/00023210-200721020-00004
M3 - Review article
C2 - 17284095
AN - SCOPUS:33846967064
VL - 21
SP - 129
EP - 141
JO - CNS Drugs
JF - CNS Drugs
SN - 1172-7047
IS - 2
ER -